The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II intermittent (or stop and go) l-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC: The interim report of t-CORE0901.
Makio Gamoh
No relevant relationships to disclose
Shunsuke Kato
No relevant relationships to disclose
Tomohito Niitani
No relevant relationships to disclose
Yasuko Murakawa
No relevant relationships to disclose
Masato Sakayori
No relevant relationships to disclose
Hideki Isobe
No relevant relationships to disclose
Hideki Shimodaira
No relevant relationships to disclose
Shoko Akiyama
No relevant relationships to disclose
Kozue Yoshida
No relevant relationships to disclose
Takashi Yoshioka
No relevant relationships to disclose
Chikashi Ishioka
Research Funding - Chugai Pharma; Novartis